A recent review found that new methods of treatment for prurigo nodularis had promising results, including approaches that target interleukin 31 and its receptor. A review published in Dermatology and ...

Vixarelimab showed rapid, sustained itch reduction and good safety in prurigo nodularis. Learn more about the study and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA has ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25 th World Congress of Dermatology (WCD) in Singapore. The results highlight ...

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

DelveInsight's Prurigo Nodularis Market Insights report includes a comprehensive understanding of current treatment practices, prurigo nodularis emerging drugs, market share of individual therapies, ...

Please provide your email address to receive an email when new articles are posted on . By week 12, itch and pain scores decreased 78.3% and 53.7% in the prurigo nodular and chronic pruritus of ...

The Business Research Company's Key Trend Shaping The Nodular Prurigo Market In 2025: Regulatory Approvals Driving Innovation In The Market It will grow to $3.06 billion in 2029 at a compound annual ...

The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults with ...

Data Bridge Market Research recently conducted an in-depth market intelligence study focusing on the Nodular Prurigo Market. The newly published report presents vital data using visually engaging ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Sanofi has initiated a non-interventional ...